Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen Daniel Wiviott, M.D.

Co-Author

This page shows the publications co-authored by Stephen Wiviott and Benjamin Scirica.
Connection Strength

3.251
  1. Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SD. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020 Mar 17; 75(10):1095-1106.
    View in: PubMed
    Score: 0.987
  2. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 01 15; 139(3):366-375.
    View in: PubMed
    Score: 0.228
  3. Bohula EA, Wiviott SD, Scirica BM. Lorcaserin Safety in Overweight or Obese Patients. N Engl J Med. 2019 01 03; 380(1):100.
    View in: PubMed
    Score: 0.227
  4. Waks JW, Sabatine MS, Cannon CP, Morrow DA, Gibson CM, Wiviott SD, Giugliano RP, Sloan S, Scirica BM. Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6.
    View in: PubMed
    Score: 0.161
  5. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 03; 369(14):1317-26.
    View in: PubMed
    Score: 0.157
  6. Scirica BM, Kadakia MB, de Lemos JA, Roe MT, Morrow DA, Li S, Wiviott SD, Kontos MC. Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. Clin Chem. 2013 Aug; 59(8):1205-14.
    View in: PubMed
    Score: 0.153
  7. Shah RV, Holmes D, Anderson M, Wang TY, Kontos MC, Wiviott SD, Scirica BM. Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. Circ Heart Fail. 2012 Nov; 5(6):693-702.
    View in: PubMed
    Score: 0.147
  8. Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SD. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6.
    View in: PubMed
    Score: 0.132
  9. Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BM. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.122
  10. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008 Apr 19; 371(9621):1353-63.
    View in: PubMed
    Score: 0.108
  11. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7.
    View in: PubMed
    Score: 0.103
  12. Scirica BM, Morrow DA, Sadowski Z, Ruda M, Nicolau JC, Giugliano RP, Wiviott SD, Sabatine MS, Shui A, Antman EM, Braunwald E. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.
    View in: PubMed
    Score: 0.102
  13. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.
    View in: PubMed
    Score: 0.095
  14. Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 Nov 05; 140(19):1569-1577.
    View in: PubMed
    Score: 0.059
  15. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018 11 24; 392(10161):2269-2279.
    View in: PubMed
    Score: 0.056
  16. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018 09 20; 379(12):1107-1117.
    View in: PubMed
    Score: 0.055
  17. Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MS. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. Am Heart J. 2018 08; 202:39-48.
    View in: PubMed
    Score: 0.054
  18. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O'Donoghue ML, Murphy SA, Morrow DA. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2309-17.
    View in: PubMed
    Score: 0.043
  19. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2318-26.
    View in: PubMed
    Score: 0.043
  20. Rhee JW, Wiviott SD, Scirica BM, Gibson CM, Murphy SA, Bonaca MP, Morrow DA, Mega JL. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. Clin Cardiol. 2014 Jun; 37(6):350-6.
    View in: PubMed
    Score: 0.040
  21. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12; 366(15):1404-13.
    View in: PubMed
    Score: 0.035
  22. Kadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BM. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). JACC Cardiovasc Interv. 2010 Nov; 3(11):1166-77.
    View in: PubMed
    Score: 0.032
  23. Lopes RD, Peterson ED, Chen AY, Roe MT, Wang TY, Ohman EM, Magid DJ, Ho PM, Wiviott SD, Scirica BM, Alexander KP. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC Cardiovasc Interv. 2010 Jun; 3(6):669-77.
    View in: PubMed
    Score: 0.031
  24. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009 Jun 02; 119(21):2758-64.
    View in: PubMed
    Score: 0.029
  25. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Shui A, Qin J, Scirica B, Bradner JE, Jang IK, Gibson CM, Antman EM. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007 Dec 15; 100(12):1734-8.
    View in: PubMed
    Score: 0.026
  26. Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol. 2007 Feb 01; 99(3):344-8.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.